Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

By Jeffrey S. Weber, S. D’Angelo, D. Minor, F. Hodi, R. Gutzmer, B. Neyns, C. Hoeller, N. Khushalani, Wilson H. Miller, C. Lao and 18 more. The Lancet Oncology, 2015

2,546 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/5fab711e2a3554dd0f6c21d819454fea23190f21

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Molecular Biology

In Oncology

Citations in the corpus

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “Elevations in lipase levels have been reported in studies of both anti-CTLA-4 and anti-PD-1/PD-L1 mAb [1, 7, 8].”
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors (2015, neutral): “Non–small cell lung cancer 5 (29) 1 (8) 6 (20)”
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations (2018, background): “second-line treatment of unresectable or metastatic melanoma based on the CheckMate 037 trial [18].”
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019, background): “Subsequent phase III studies of nivolumab as monotherapy in treatment-naive and previously treated advanced melanoma yielded durable response rates of 32% and 40%, respectively [9, 11].”
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence (2020, methodology): “Thereafter, based on the improved recurrence-free survival (RFS) rate from CheckMate-238 trial on 20 December 2017, the FDA further expanded its indication in lymph node-positive or metastatic melanoma patients who had undergone complete resection [36] (Category 1).”
Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses (2015, positive): “Similar sharp high versus low clustering is seen for subgroups of breast and lung cancers and melanoma (Guan et al., 2015) (Figures S7D– S7F), the last being very responsive to immune checkpoint therapy (Topalian et al., 2015; Hodi et al., 2010; Weber et al., 2015).”
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “1% to 17%).(99,100) If anemia progresses to pancytopenia or multiple cell lines are affected,(101) evaluation for pure red cell aplasia,(102) autoantibodies,(103) aplastic anemia, and myelodysplasia must be considered.”
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Anti-PD1 therapies are also recommended as a second-line treatment, after ipilimumab failure [43, 44].”
Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data (2021, positive): “Immune checkpoint blockade (ICB) has achieved exciting results in a wide variety of cancers 25, 26 .”